Moreover, dual combination of nivolumab (PD-1) and ipilimumab (CTLA-4) with azacitidine in relapsed and in frontline elderly AML therapy has recently begun enrollment (NCT02397720). This evidence concerns the gene CTLA4 and acute myeloid leukemia.